Author

JP Holmes

Abstract P5-16-02: Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vaccine

2012 · TJ Vreeland, GT Clifton, et al. · Cancer Research · 7

P1-13-01: An Update of a Phase II Trial of the HER2 Peptide AE37 Vaccine in Breast Cancer Patients To Prevent Recurrence.

2011 · DF Hale, S Perez, et al. · Cancer Research · 4

P1-13-02: Long-Term Clinical Benefit of Adjuvant Breast Cancer Vaccine: 5 Year Efficacy of E75 with Multiple Booster Inoculations.

2011 · TJ Vreeland, GT Clifton, et al. · Cancer Research · 2

Abstract P2-09-01: Subgroups analysis of a multicenter, prospective, randomized, blinded phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for prevention of recurrence in breast cancer patients

2019 · GT Clifton, PM Kemp Bohan, et al. · Cancer Research · 1

Abstract P2-20-03: Combination Immunotherapy for Breast Cancer Patients: Safety and Immunologic Data from a Phase II Trial Administering a HER2/neu-Derived Peptide vaccine (AE37+GM-CSF) Sequentially or Concurrently with Trastuzumab in the Adjuvant Setting

2010 · EA Mittendorf, SA Perez, et al. · Cancer Research · 1

Circulating regulatory (CD4+CD25+FOXP3+) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/neu peptide (AE37).

2009 · JD Gates, LC Benavides, et al. · Cancer Research · 1

Incidence of hormone-receptor negative and basal type breast tumors among HLA-A2+ patients and possible implications for cancer vaccine trials: U.S. Military Cancer Institute clinical trials group study I-01, I-02, I-03, and I-04.

2009 · JP Holmes, LC Benavides, et al. · Cancer Research · 1

Abstract P2-09-09: Initial safety and efficacy of a phase I/IIa trial of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer

2019 · S Bhattacharya, JP Holmes, et al. · Cancer Research

Abstract P2-20-02: Increased Prevalence of HLA-DR3 among Breast Cancer Patients: Implications for Adjuvant Her2/neu Peptide Vaccine Trials

2010 · MD Olson, GT Clifton, et al. · Cancer Research

Abstract P2-20-01: Safety and Clinical Efficacy of Multiple Booster Inoculations with the E75 Adjuvant Breast Cancer Vaccine

2010 · TJ Vreeland, GT Clifton, et al. · Cancer Research

Optimal method of dosing HER2/neu peptide vaccines: U.S. Military Cancer Institute Clinical Trials Group Study 1-01, 1-02, 1-03, and 1-04.

2009 · LC Benavides, JD Gates, et al. · Cancer Research

Works count: 11

Citation count: 17

H-index: 2

I10-index: